High Normal Blood Pressure
Conditions
Interventions
Experimental group:Tanyutongzhi antihypertensive decoction
Control group:Placebo
Sponsors
Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily participate and sign the informed consent form; 2. Age range: 18 years old = age < 65 years old; 3. Individuals with prehypertensive blood pressure levels ranging from 130 to 139 mmHg (systolic) and 85 to 89 mmHg (diastolic); 4. =3 cardiovascular risk factors including at least one of abdominal obesity obesity or dyslipidemia; 5. Diagnosis according to Traditional Chinese Medicine (TCM) syndrome differentiation as a syndrome of intermingled phlegm and blood stagnation; 6. Subjects have not taken any antihypertensive medications (including western medicine Chinese patent medicine traditional Chinese herbs and intravenous formulations) or undergone any external therapeutic treatments for the purpose of lowering blood pressure such as acupuncture moxibustion acupoint application etc. within the past month.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with primary or secondary hypertension; 2. History of cerebrovascular diseases such as cerebral hemorrhage ischemic stroke transient ischemic attack and cerebral infarction; 3. Coexisting conditions including coronary heart disease myocardial infarction angina pectoris heart failure and arrhythmic histories such as atrial fibrillation Wolff-Parkinson-White syndrome conduction blocks as well as other diseases requiring long-term use of medications that overlap with antihypertensive drugs regardless of the purpose of use; 4. Coexisting hypertensive target organ damage chronic kidney disease (CKD) stage =3 peripheral artery disease retinopathy diabetes hematological disorders autoimmune diseases hyperthyroidism malignancy cognitive impairment and psychiatric disorders; 5. History of surgery within the past year; 6. Severe liver dysfunction: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels exceeding 3 times the normal range; 7. Patients requiring hormone or antidepressant therapy due to coexisting conditions; 8. Pregnant or lactating women; 9. Individuals with allergic constitutions; 10. Participants concurrently involved in other drug clinical studies; 11. Other situations deemed unsuitable for participation in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antihypertensive efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine Syndrome Score;Triglycerides;Hypertension progression rate;High-density lipoprotein cholesterol;Total cholesteral;Low-density lipoprotein cholesterol;1-year antihypertensive efficiency; | — |
Countries
China
Contacts
Public ContactWang Liying
Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Science
Outcome results
None listed